Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Bayer HealthCare AG
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
The Einstein CYP cohort study. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism using a strong CYP 3A4 inducer
The primary objective is to characterize the population PK/PD of an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (DVT) or acute pulmonary embolism (PE) and co...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Oral rivaroxaban in young children with venous thrombosis Rivaroxaban oral en niños con trombosis venosa
to assess the incidence of major bleeding and clinically relevant non-major bleeding Evaluar la incidencia de hemorragias graves y de hemorragias no graves clínicamente relevantes
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
To assess the efficacy and safety of oral BAY 63-2521 in patients with inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) or recurrent or persisting pulmonary hypertension after surgical...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Explore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in subjects with nonvalvular atrial fibrillation scheduled for cardioversion Εξέταση της αποτελεσματικότητας και της ασφάλειας της από του στόματος αγωγής άπαξ ημερησίως με rivaroxaban για την πρόληψη καρδιαγγειακών συμβαμάτων σε ασθενείς με μη-βαλβιδική κολπική μαρμαρυγή στους οποίους έχει προγραμματιστεί καρδιοανάταξη
The primary efficacy and safety objectives are to explore the efficacy of rivaroxaban compared with that of dose-adjusted vitamin K antagonists (VKA) in the prevention of the events with regard to the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A phase II, multi-centre, open-label, uncontrolled study to evaluate the efficacy and safety of BAY 43-9006 given daily in combination with repeated 21-day cycles of dacarbazine (DTIC) chemotherapy in subjects with advanced metastatic melanoma
To evaluate the overall tumour response rate (including complete responses (CR) and partial responses (PR)) of oral BAY 43-9006 given continuously in combination with repeated 21-day cycles of dacarba...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 μg/h, 100 μg/h, 150 μg/h) Given Intravenously to Subjects with Acute Decompensated Chronic Congestive Heart Failure (ADHF) within 12 hours after hospital admission (Pulmonary Artery Catheter eg, Swan-Ganz not required
To investigate the safety and efficacy of a fixed dose of intravenous BAY 58-2667 (50 μg/h, 100 μg/h, or 150 μg/h) over at least 24 hours and up to 48 hours in subjects with ADHF needin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A clinical trial investigating safety and efficacy of a long-acting factor VIII in children (age <12 years) with severe hemophila A
To evaluate pharmacokinetics, safety, and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated patients with hemophilia A Expansion group (Part 2) To further evalu...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Study to research BAY 1021189 in patients with worsening heart failure with reduced ejection fraction Studio di Fase IIb sulla sicurezza ed efficacia di quattro regimi posologici di BAY 1021189 in pazienti con HfrEF affetti da insufficienza cardiaca cronica in via di peggioramento (SOCRATES-REDUCED)
To find the optimal dose of BAY 1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment by characterizing the safety, tolerability, pharmacodynamic effects, ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A multicenter Phase III uncontrolled open-label trial to evaluate safety and efficacy of BAY 81-8973 in children with severe haemophilia A under prophylaxis therapy En multicenter fas III okontrollerad öppen prövning för att utvärdera säkerheten och effekten av BAY 81-8973 hos barn med svår hemofili A enligt profylax behandling
The primary objective is to evaluate the safety and efficacy of the treatment with BAY 81-8973 for prophylaxis and treatment of breakthrough bleeds in children with haemophilia A
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Exploring the efficacy of once daily oral rivaroxaban for treatment of thrombus in left atrial/left atrial appendage in subjects with nonvalvular atrial fibrillation or atrial flutter Ocena skuteczności rywaroksabanu podawanego doustnie jeden raz na dobę, w leczeniu skrzepliny w lewym przedsionku / uszku lewego przedsionka u pacjentów z migotaniem przedsionków niezwiązanym z wadą zastawkową lub u pacjentów z trzepotaniem przedsionków
The primary objective of the study is to explore the effect of rivaroxaban on the complete resolution of LA/LAA thrombi at the end-of-treatment visit (after 6 weeks of treatment) in subjects with no...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant